Literature DB >> 21700351

Radioresistant head and neck squamous cell carcinoma cells: intracellular signaling, putative biomarkers for tumor recurrences and possible therapeutic targets.

Sergej Skvortsov1, Connie R Jimenez, Jaco C Knol, Paul Eichberger, Bernhard Schiestl, Paul Debbage, Ira Skvortsova, Peter Lukas.   

Abstract

PURPOSE: Treatment of local and distant head and neck cancer recurrences after radiotherapy remains an unsolved problem. In order to identify potential targets for use in effective therapy of recurrent tumors, we have investigated protein patterns in radioresistant (FaDu-IRR and SCC25-IRR, "IRR cells") as compared to parental (FaDu and SCC25) head and neck carcinoma cells. METHODS AND MATERIALS: Radiation resistant IRR cells were derived from parental cells after repeated exposure to ionizing radiation 10 times every two weeks at a single dose of 10 Gy, resulting in a total dose of 100 Gy. Protein profiling in parental and IRR cells was carried out using two-dimensional differential gel electrophoresis (2D-DIGE) followed by MALDI-TOF/TOF mass spectrometry. Cell viability, cell migration assays and Western blot analysis were used to confirm results obtained using the proteome approach.
RESULTS: Forty-five proteins that were similarly modulated in FaDu-IRR and SCC25-IRR cells compared to parental cells were selected to analyze their common targets. It was found that these either up- or down-regulated proteins are closely related to the enhancement of cell migration which is regulated by Rac1 protein. Further investigations confirmed that Rac1 is up-regulated in IRR cells, and inhibiting its action reduces the migratory abilities of these cells. Additionally, the Rac1 inhibitor exerts cytostatic effects in HNSCC cells, mostly in migratory cells.
CONCLUSIONS: Based on these results, we conclude that radioresistant HNSCC cells possess enhanced metastatic abilities that are regulated by a network of migration-related proteins. Rac1 protein may be considered as a putative biomarker of HNSCC radiation resistance, and as a potential therapeutic target for treating local and distant HNSCC recurrences. Copyright Â
© 2011 Elsevier Ireland Ltd. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21700351     DOI: 10.1016/j.radonc.2011.05.067

Source DB:  PubMed          Journal:  Radiother Oncol        ISSN: 0167-8140            Impact factor:   6.280


  17 in total

1.  MAGE-A9 in head and neck cancer: Prognostic value and preclinical findings in the context of irradiation.

Authors:  Till J Meyer; Stefan Hartmann; Gisela Wohlleben; Muna Brisam; Axel Seher; Alexander C Kübler; Bülent Polat; Urs D A Müller-Richter
Journal:  Mol Clin Oncol       Date:  2018-01-19

Review 2.  Reshaping the systemic tumor immune environment (STIE) and tumor immune microenvironment (TIME) to enhance immunotherapy efficacy in solid tumors.

Authors:  Liangliang Xu; Chang Zou; Shanshan Zhang; Timothy Shun Man Chu; Yan Zhang; Weiwei Chen; Caining Zhao; Li Yang; Zhiyuan Xu; Shaowei Dong; Hao Yu; Bo Li; Xinyuan Guan; Yuzhu Hou; Feng-Ming Kong
Journal:  J Hematol Oncol       Date:  2022-07-07       Impact factor: 23.168

Review 3.  Rho GTPases in cancer radiotherapy and metastasis.

Authors:  Rui-Jie Zeng; Chun-Wen Zheng; Wan-Xian Chen; Li-Yan Xu; En-Min Li
Journal:  Cancer Metastasis Rev       Date:  2020-08-08       Impact factor: 9.264

4.  Rac1 as a potential therapeutic target for chemo-radioresistant head and neck squamous cell carcinomas (HNSCC).

Authors:  S Skvortsov; J Dudás; P Eichberger; M Witsch-Baumgartner; J Loeffler-Ragg; C Pritz; V H Schartinger; H Maier; J Hall; P Debbage; H Riechelmann; P Lukas; I Skvortsova
Journal:  Br J Cancer       Date:  2014-05-01       Impact factor: 7.640

5.  Rac1 as a multifunctional therapeutic target to prevent and combat cancer metastasis.

Authors:  Sergej Skvortsov; Ira-Ida Skvortsova; Christoph R Arnold; Alshaimaa Abdelmoez; Gudrun Thurner; Paul Debbage; Peter Lukas
Journal:  Oncoscience       Date:  2014-08-21

6.  Inhibition of glutamine metabolism counteracts pancreatic cancer stem cell features and sensitizes cells to radiotherapy.

Authors:  Doudou Li; Zhiqiang Fu; Ruiwan Chen; Xiaohui Zhao; Yu Zhou; Bing Zeng; Min Yu; Quanbo Zhou; Qing Lin; Wenchao Gao; Huilin Ye; Jiajia Zhou; Zhihua Li; Yimin Liu; Rufu Chen
Journal:  Oncotarget       Date:  2015-10-13

7.  Rac1 overexpression is correlated with epithelial mesenchymal transition and predicts poor prognosis in non-small cell lung cancer.

Authors:  Yujuan Zhou; Qianjin Liao; Yaqian Han; Jie Chen; Zhigang Liu; Hang Ling; Jing Zhang; Wenjuan Yang; Linda Oyang; Longzheng Xia; Li Wang; Heran Wang; Lei Xue; Hui Wang; Bingqiang Hu
Journal:  J Cancer       Date:  2016-10-23       Impact factor: 4.207

8.  Reactive oxygen species and p21Waf1/Cip1 are both essential for p53-mediated senescence of head and neck cancer cells.

Authors:  A L Fitzgerald; A A Osman; T-X Xie; A Patel; H Skinner; V Sandulache; J N Myers
Journal:  Cell Death Dis       Date:  2015-03-12       Impact factor: 8.469

9.  Association of RAC1 Gene Polymorphisms with Primary End-Stage Renal Disease in Chinese Renal Recipients.

Authors:  Yani Liu; Jiali Zhou; Xiaomei Luo; Chunxiao Yang; Yu Zhang; Shaojun Shi
Journal:  PLoS One       Date:  2016-02-03       Impact factor: 3.240

10.  Metastatic HPV-related oropharyngeal carcinoma cured with chemoradiotherapy: importance of pretherapy biomolecular assessment.

Authors:  Francesco Perri; Francesco Longo; Giuseppina Della Vittoria Scarpati; Salvatore Pisconti; Vito Longo; Raffaele Addeo; Fabio Carducci; Carlo Buonerba; Franco Fulciniti; Raffaele Solla
Journal:  Clin Case Rep       Date:  2017-11-24
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.